Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study

[1]  I. Fentiman,et al.  Inflammation and breast cancer , 2013 .

[2]  Václav Kašička,et al.  Amino acids, peptides and proteins , 2011, Electrophoresis.

[3]  B. Nordestgaard,et al.  C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. , 2010, European heart journal.

[4]  D. McMillan,et al.  Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[6]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[7]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[8]  R. Xiang,et al.  Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model , 2009, PloS one.

[9]  H. Gruber,et al.  Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis , 2008, Breast Cancer Research.

[10]  C. Ulrich,et al.  Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[12]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[13]  S. Bojesen,et al.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[15]  F. Berrino,et al.  Serum Insulin-Like Growth Factor-I and Platelet-Derived Growth Factor as Biomarkers of Breast Cancer Prognosis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  B. Nordestgaard,et al.  Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. , 2008, Circulation.

[17]  C. Meisinger,et al.  Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. , 2008, Clinical chemistry.

[18]  H. Mouridsen,et al.  The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise , 2008, Acta oncologica.

[19]  L. Hefler,et al.  Association of Elevated C-reactive Protein Levels With an Impaired Prognosis in Patients With Surgically Treated Endometrial Cancer , 2007, Obstetrics and gynecology.

[20]  P. Speiser,et al.  C-reactive protein is a prognostic parameter in patients with cervical cancer. , 2007, Gynecologic oncology.

[21]  D. Lawlor,et al.  A systematic review of the association between circulating concentrations of C reactive protein and cancer , 2007, Journal of Epidemiology and Community Health.

[22]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[23]  C. McArdle,et al.  Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer , 2007, British Journal of Cancer.

[24]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[25]  Alberto Mantovani,et al.  Inflammation and cancer: breast cancer as a prototype. , 2007, Breast.

[26]  D C McMillan,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer , 2006, British Journal of Cancer.

[27]  Edward R. Ashwood,et al.  Tietz Textbook of Clinical Chemistry and Molecular Diagnostics , 2005 .

[28]  N. Brünner,et al.  High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival , 2003, Breast Cancer Research and Treatment.

[29]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[30]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[31]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[32]  R. Blamey,et al.  Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[33]  M. Williams,et al.  An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. , 1990, British Journal of Cancer.

[34]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.